한국적 의학 기준에 근거한 고혈압환자의 Angiotensin II Receptor Blockers와 Calcium Channel Blockers의 약물 평가 = Evaluation of Therapeutic Differences of Angiotensin II Receptor Blockers and Calcium Channel Blockers Among Hypertensive Patients Classified by Oriental Traditional Way

다국어 초록 (Multilingual Abstract)

Oriental lifestyle for treating diseases has been developed and well-accepted for a long time
among Koreans. Sasang Constitution theory, originated from Korean traditional medicine, suggests that medication treat-ment should be differentiated by each patient’s body classification (So-yang [SY], So-eum [SE], Tae-yang [TY], and Tae-eum [TE]), in contrary to western medicine’s theory that medication should be applied equally by disease indication without such classification. However, the pharmacotherapeutic outcomes of these theories have not been compared to date. In this study, we aimed to compare the two theories by evaluating blood pressure (BP), which is lowered as a therapeutic outcome, among hypertensive patients taking angiotensin II receptor blockers (ARBs) or calcium channel blockers (CCBs), two most com-monly used antihypertensive classes in Korea. Methods: From April 2006 to June 2012, we retrospectively collected data on hypertensive patients with Sasang Constitution classification at Kyunghee University Hospital at Gangdong, one of the East-West collaborative medical centers in Korea. We collected information on age, gender, underlying diseases, anti-hypertensive drugs (ARB, CCB, ARB+CCB), and BP by reviewing the electronic medical records. We excluded patients with missing blood pressure at baseline or follow-up, or those who had a change in their antihypertensive drug class during follow-up. Results: We selected a total of 573 patients (SY: 165, SE: 158, TY: 0, TE: 250). Baseline BPs were on average 139.0/82.0 mmHg for SY, 137.8/78.5 mmHg for SE, and 138.7/79.2 mmHg for TE. In all three groups, CCBs were the most
prescribed, followed by combination therapy with ARB+CCB, then ARBs. BP reduction after 1 month of initial medication was significantly different among the drug classes, but not in Sasang constitutional classification (ARB [SY: -12.4/-4.7, SE:-12.3/-2.5, TE: -8.6/-1.8], CCB [SY: -12.3/-5.4, SE: -13.0/-2.3, TE: -10.8/-6.0], ARB+CCB [SY: -15.6/-6.7, SE: -18.4/-8.1, TE:-20.2/-6.7], drug [P≤0.05/P>0.05], constitutional type [P>0.05/P>0.05]). Conclusion: We observed significant differences in reduction of blood pressure by classes of drugs (ARB+CCB>CCB>ARB) but not by Sasang constitutional classification. Therefore, current approach of antihypertensive pharmacotherapy assisted by Western medicine is appropriate for treat-ment of hypertension. However, further larger scale or prospective studies are required in order to confirm these results.

목차 (Table of Contents)

• Methods
• Results
• Discussion
• Acknowledgement
• References

참고문헌 (Reference)

1 김종원, "연령군에 따른 사상체질별 체형 평가" 대한동의병리학회 21 (21): 258-262, 2007

2 전은영, "사상체질식이 적용이 본태성 고혈압 환자의 혈압, 비만도 및 혈중지질에 미치는 효과: 유산소 운동과 저염식이 병용환자를 대상으로" 한국간호과학회 32 (32): 673-683, 2002

3 신미숙, "국내 임상한의사의 고혈압 한방치료 인식 및 실태조사" 대한침구의학회 25 (25): 23-33, 2008

4 성예나, "고혈압 환자의 혈압강하제 처방양상- 외래 처방전을 중심으로" 한국임상약학회 19 (19): 167-179, 2009

5 김민종, "四象體質에 따른 고혈압 유병률 및 위험인자" 사상체질의학회 21 (21): 150-164, 2009

6 이태규, "一個 綜合病院 健康檢診者의 四象體質에 따른 慢性疾患의 有病率에 關한 硏究" 사상체질의학회 17 (17): 32-45, 2005

7 Philipp, T., "Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension" 29 : 563-, 2007

8 Rosendorff, C., "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention" 115 : 2761-, 2007

9 National Heart, Lung, and Blood Institute, "The seventh report of the Joint National Committee on prevention, detection, evaluation andt reatment of high blood pressure, NIH Publication No.03-5233:2003"

10 Chrysant, S. G., "The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-bline, controlled, 8-week factorial efficacy and safety study" 30 : 587-, 2008

11 Neutel, J. M., "Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients" 24 : 2389-, 2008

12 Lee, J. H., "Oriental medication of Hypertension" 23 : 1739-, 1999

13 Korean Association of Pharmacy Education, "Organiazion of Pharmacology, Pharmacology" Shinil 2009

14 Go, A. S., "Executive Summary: Heart Disease and Stroke Statistics--2013 Update: A Report From the American Heart Association" 127 : 143-, 2013

15 Hansson, L., "Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT)randomised trial" 351 : 1755-, 1998

16 Turnbull, F., "Effects of different blood-pressure lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials" 362 : 1527-, 2003

17 Lee, J. M., "Dong-Yi-Soo-Se-Bo-Won"

18 Lee, S. W., "Development of standard on constitutional health status" 44 : 2009

19 Alan, H. G., "Combination therapy in hypertension" 4 : 90-, 2010

20 Koda-Kimble, M. A., "Applied therapeutcis: The clinical use of drugs" Lippincott 2009

21 Chae, H., "An Alternative way to individualized medicine:Psychological and Physical traits of Sasang Typology" 9 : 519-, 2003

22 Moreira, L. B., "Alcohol intake and blood pressure; the importance of time elapsed since last drink" 16 : 175-, 1998

23 Hazarus, J. M., "Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group" 29 : 641-, 1997

24 The Task Force for the management of Arterial Hypertension of the European Society of Hypertension (SEH) and of the European Society of Cardiology (ESC), "2007 guidelines for the management of arterial hypertension" 25 (25): 1105-, 2007